The best partner
for advanced clinical research
Proven expertise in rare diseases, orphan drugs, first-in-human studies, and advanced therapies.
Deep knowledge of the European regulatory framework.
Solid experience in rare diseases, orphan drugs, first in human and advanced therapies.
Widespread knowledge of the Italian regulatory framework.
Agile organizational structure with fast and flexible decision-making processes.
Fully owned by a team of experienced clinical research professionals.
Solid and long-standing partnerships supporting international clinical trials.
Hippocrates Research (HR) is a Contract Research Organization (CRO) within the Hippocrates Group, providing high-quality clinical research services across the full development lifecycle.
Team
90% women, 95% graduates, employee turnover 2,6% (2023-2025) 10 times lower than the European industry average and highly trained staff supported by external senior managers
Regulatory qualifications
Hippocrates Research is qualified by: AIFA, EMA, and ENCePP
Features
Digital clinical trials (including e-CRF, e-TMF and e-PRO), Decentralized trials, Pragmatic trials, Remote monitoring, Phase I units accreditation, Full statistical and data management services
Quality
ISO 9001:2015, ISO UNI PDR 125:2022 certified, Ecovadis rated, SIMeF – GIQAR affiliates, fully GDPR compliant with an independent Data Protection Officer (DPO), UN Global Compact Member
Finance
Debt free Company, Privatly owned company and Customer retention rate 84% (by value)
Our core business
Our ambition is to be a best-in-class, full-service Contract Research Organization, internationally recognized for excellence in clinical research.
Hippocrates Research serves customers across Europe (57%), Italy (30%), North America and Japan (13%). Approximately 80% of HR’s annual revenues derive from clinical research–related services, including regulatory consultancy, primarily delivered to non-Italian sponsors.
With customer retention rates exceeding 64%, Hippocrates Research has more than doubled the number of international studies in the last five years compared to the previous quinquennium, confirming long-term trust from global sponsors.
HR supports clinical studies in Europe across the entire development lifecycle, from first-in-human to Phase IV, which currently accounts for approximately 50% of total revenues.
More than 40% of total turnover is generated by Non-Interventional Studies (NIS), including PASS, while over 10% comes from medical devices and food supplements.
With over 3,600 activated clinical sites and 203 studies delivered across Europe, Hippocrates Research combines scale and specialization to support complex clinical programs. Our recognized expertise spans high-impact therapeutic areas including Dermatology, Cardiology, Oncology, and Gastroenterology, complemented by strong capabilities in Ophthalmology, Neurology, Urology, Sexual Health, Pneumology, Psychiatry, and Infectious Diseases.
Interventional PHASE I/IV
NISS/PASS
MD
Nutraceutical
Original features and innovation
Hippocrates Research delivers fully digital interventional clinical trials, achieving over a 70% reduction in on-site study visits and enabling more than 90% of efficacy data to be generated and collected remotely.
Advanced remote monitoring technologies, combined with proven operational expertise, allow up to 90% of source data verification (SDV) to be performed remotely at site level.
HR leverages a broad, nationwide network of GCP-trained general practitioners and paediatricians, supporting interventional Phase III–IV studies, non-interventional studies, and food supplement trials.
Strategic partnerships with leading Italian universities further strengthen HR’s capabilities, supporting preclinical research activities in gastroenterology and dermatology. Through dedicated operational units, HR also provides tailored solutions for pragmatic and decentralized clinical trials.
Clients
